Popular Articles

Results From 8 Late-Breaking Clinical Trials Presented At Heart Failure 2009
Results and updates from eight studies were presented during a late-breaking trials session at Heart Failure 2009. Reviewing them at a press conference, Professor John McMurray, President of the Heart Failure Association, described the trials" objectives and main implications.
new payday loan lenders
Must We Keep Depriving Residents Of Sleep?
Before reducing or changing working hours for medical residents in Canada, a thorough evaluation of the impact on the educational experience and acquisition of skills should be conducted, write Dr. Diane Kelsall and the CMAJ editorial team. This will ensure that Canadians will benefit from the skills of a healthy, well-trained resident workforce.
News of the day
Positive, Clinically Significant Phase III Results For Personalized Anti-Cancer Vaccine, BiovaxID®, Presented At ASCO Plenary Session
Biovest International, Inc. (Other OTC: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ) announced that an eight year pivotal, randomized, multi-center, double-blind, controlled Phase III clinical study has shown that BiovaxID® (personalized therapeutic anti-cancer vaccine) significantly prolonged disease-free survival in follicular non-Hodgkin"s lymphoma. The study, which is being featured at today"s American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine - an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first ever vaccine targeting lymphoma to demonstrate such a disease-free survival benefit.
Endocrinology

$20 Million NIH Grant To Transform Clinical Research At UIC

The National Institutes of Health has awarded a five year $20 million grant to the University of Illinois at Chicago"s Center for Clinical and Translational Science. The grant is the largest in UIC"s history. "The CCTS draws upon the rich intellectual breadth of the UIC campus and adds to the portfolio of excellent research that is underway on the campus," said Paula Allen-Meares, UIC chancellor. Translational research -- moving new, basic science knowledge into useful applications for health and medicine -- is "an urgent need and a continuing challenge," says R. Michael Tanner, UIC provost and vice chancellor for academic affairs. "Insights from basic research need much development and further study to create beneficial clinical practices, and the NIH is funding us to accelerate the process," Tanner said. The NIH launched the Clinical Translational Science Award program in 2006 to fund a national consortium of medical research institutions that now includes 39 leading centers in 23 states. When the program is fully implemented, about 60 centers will be connected with an annual budget of $500 million. The UIC center was established in 2007 to create new collaborations and support the movement of knowledge from the lab bench into the community. "This grant enables UIC to enhance its collaborative research in the health sciences, from basic science to community engagement, bringing in virtually all the colleges at UIC as well as great collaborations with the Urbana-Champaign campus, and the medical campuses at Peoria and Rockford," said Dr. Joseph Flaherty, dean of the UIC College of Medicine. The scope of the collaborations make the UIC center "unique as a statewide translational science program," he said. "This is an important award for UIC," said Dr. Larry Danziger, UIC interim vice chancellor for research. "We are excited about the ways in which this award will facilitate increased collaborations among our basic science and clinical researchers on campus, our local community partners, and our national peers to move basic science findings more quickly into clinical trial and community settings." The center provides a Web-based as well as a geographic single point-of-access for investigators -- including a match-making service to identify potential new collaborations. To provide support for research, the center offers six "core" services: statistical design and analysis, clinical interface, biomedical informatics, regulatory support and advocacy, community engagement and research, and translational technologies and res. The center includes educational programs for pre- and postdoctoral trainees and faculty researchers to train the next generation of translational researchers. Some projects already funded by the center include developing a collaborative research program in asthma and allergic diseases, exploring a promising immunotherapy to treat severe infections in patients with compromised immune systems, and a multi-disciplinary approach to improving cancer care for rural residents. The center also includes researchers at Advocate Health Care and the Jesse Brown VA Medical Center. "The center will capitalize on mature conceptual and technological res at UIC to foster collaboration and innovation," said Theodore Mazzone, professor of medicine and director of the center. "Our goal is to facilitate the work of translational investigators, to make it easier and more attractive for them to think beyond traditional disciplinary boundaries." For more information on this grant go to: http://www.nih.gov/news/health/jul2009/ncrr-14.htm. Jeanne Galatzer-Levy University of Illinois at Chicago


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):